Oxycodone DETERx + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Low Back Pain

Conditions

Chronic Low Back Pain

Trial Timeline

Aug 1, 2012 → Jul 1, 2014

About Oxycodone DETERx + Placebo

Oxycodone DETERx + Placebo is a phase 3 stage product being developed by Collegium Pharmaceutical for Chronic Low Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01685684. Target conditions include Chronic Low Back Pain.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Low Back Pain were approved

Approved (20) Terminated (3) Active (0)
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
alefaceptAstellas PharmaApproved
AlefaceptAstellas PharmaApproved
lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01685684Phase 3Completed

Competing Products

20 competing products in Chronic Low Back Pain

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25